Treatment of male osteoporosis: Recent advances with alendronate

Osteoporosis International

Volumn 13, Issue 3, 2002, Pages 195-199

  Ringe, J D ^a   Orwoll, E ^b   Daifotis, A ^c   Lombardi, A ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; PLACEBO;

ADULT; AGED; BODY HEIGHT; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; HUMAN; MALE; META ANALYSIS; MULTICENTER STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADULT; AGED; ALENDRONATE; BONE DENSITY; BONE RESORPTION; CALCIUM; FEMALE; FRACTURES, BONE; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; TESTOSTERONE;

EID: 0036117810     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200013     Document Type: Review

References (59)

1. The prevention and treatment of osteoporosis
2. The economic and human costs of osteoporotic fracture
3. Osteoporosis in men
4. Hip fractures in the elderly: A world-wide projection
5. The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study
6. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
7. Management of male osteoporosis: Report of the UK consensus group
8. Progressive loss of bone in the femoral neck in elderly people: Longitudinal findings from the Dubbo osteoporosis epidemiology study
9. Bone mineral density in elderly men and women: Results of the Framingham Osteoporosis Study
10. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen
11. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis
12. Severe osteoporosis in men
13. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study
14. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men
15. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men
16. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
17. Which fractures are associated with low appendicular bone mass in elderly women?
18. Bone density at various sites for prediction of hip fractures
19. Bone mineral density predicts non-spine fractures in very elderly women
20. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
21. Prediction of osteoporotic fractures by postural instability and bone density
22. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: The EVOS study
23. Bone density and fracture risk in men
24. Hip fracture prediction in elderly men and women: Validation in the Rotterdam study
25. Risk factors for hip fracture in white men: The NHANES I epidemiologic follow-up study
26. Phalangeal bone density and hip fracture risk
27. Bone mineral density and vertebral fractures in men
28. The predictive value of forearm bone mineral content measurements in men
29. Assessment of sex hormones and bone mineral density in relation to occurrence of fractures in men: A prospective population-based study
30. Characteristics of respondents and nonrespondents in a prospective study of osteoporosis
31. Calcaneal bone mineral density predicts fracture occurrence: A five-year follow-up study in elderly people
32. Risk factors for hip fracture in men from southern Europe: The MEDOS study
33. Risk factors for hip fracture in a Japanese cohort
34. Risk factors for vertebral deformities in men: Relationship to number of vertebral deformities
35. Risk factors for osteoporotic fractures in men
36. Risk factors for hip fracture in men
37. Risk factors for hip fracture in Asian men and women: The Asian osteoporosis study
38. Predictors of hip fractures in elderly men
39. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism
40. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism
41. Effects of testosterone replacement in hypogonadal men
42. Effect of testosterone treatment on bone mineral density in men over 65 years of age
43. Osteoporosis in men
44. Osteoporosis in men
45. The prevention and therapy of osteoporosis in men
46. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1(OH)-vitamin D3
47. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate
48. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
49. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
50. Prevention of nonvertebral fractures by alendronate: A meta-analysis
51. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
52. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
53. Alendronate for the treatment of osteoporosis in men
54. Alendronate treatment of established primary osteoporosis in men: Results of a 2-years prospective study
55. Effects of alendronate on bone density in men with primary and secondary osteoporosis
56. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
57. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
58. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
59. Alendronate and estrogen effects in postmenopausal women with low bone mineral density